BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending REVLIMID, in combination with dexamethasone, within its licensed indication, as an option for the treatment of patients in England and Wales with multiple myeloma who have received two or more prior therapies. NICE determined that REVLIMID, as an innovative, life-extending therapy, is a cost-effective use of National Health Service (NHS) resources.
